Bone formation and bone healing were studied in the mandible, tibia and skull bones in adult, healthy and estrogen deficient rabbits implanted with different bone substitutes. In the first study an evaluation of the differences in bone regeneration in and around solid (Alveograf *) and porous hydroxyapatite (Interpore 200*) was undertaken. The implant material was placed into experimentally made bone defects and in half of the defects hydroxyapatite was mixed with a fibrin sealant (Tisseel *). The material alone or mixed with Tisseel was also placed subperiostally in the mandible. The observation time was six month. No difference in bone regeneration was found between solid or porous hydroxyapatite granulas and the addition of Tisseel* did not seem to disturb the bone healing process. The implant material placed subperiostally did not induce bone formation nor did it provoke any bone resorption. The addition of Tisseel made the implant material much easier to handle and retain in the tissue during surgery. Bone healing around hydroxyapatite implants was also evaluated in the second study. Experimental cavities in the mandible and tibia were filled with hydroxyapatite in granules or blocks (Interpore 200*) but now with or without autolyzed, antigen-extracted, allogeneic bone (AAA). Also in this study Tisseel* was used to facilitate the handling of the material. All cavities implanted with AAA-bone, regardless of the combination with hydroxyapatite or Tisseel, demonstrated excessive bone formation resembling exostosis formation. Thus, hydroxyapatite, both as granules and blocks, can be successfully combined with AAA bone utilizing the bone inductive capacity of AAA bone. The same model was used to study the healing in ovariectomized animals in the third study. Bone cavities were implanted with or without AAA bone and left to heal. The results indicate that the osteoinductive capacity of AAA bone is in operation also in animals deprived of a normal estrogen production. The effect of using AAA bone prior to implant insertion was studied in paper four. The bone-implant contact was significant higher when AAA bone had been used. The implant stability did not seem to be affected. In paper five defects were made in skull and tibial bone in estrogen deficient animals. The deficiency of estrogen was confirmed through blood analysis, the decrease in the weight of uterus and bone mineral density. The whole body scanning with DEXA showed that the ovariectomized animals developed osteopenia. Various degree of bone formation was seen in the defects due to the influence of the bone inductive substance AAA bone. The studies indicate that a conductive material like hydroxyapatite in granules or blocks could be useful in oral reconstructive surgery. The combination with AAA bone enhanced the bone formation in calvarial and tibial bone in healthy and estrogen deficient animals. Tisseel* could be used to facilitate handling and retention of the material in the intended position during the healing process without negative effects.

Die Knochenregeneration während der Frakturheilung beinhaltet das Zusammenspiel von Wachstumsfaktoren. In einigen Patienten kommt es zu einer verzögerten oder unvollständigen Heilung. Die Gründe hierfür sind bisher nicht komplett verstanden. Neutralisierende Autoantikörper (aAB) gegen Wachstumsfaktoren oder deren Rezeptoren könnten den Heilungsprozess verzögern und potentiell beeinträchtigen In dieser Arbeit wurden 265 Frakturpatienten analysiert. Autoantikörper gegen IGF1 Rezeptor, Insulin Rezeptor, BMP7, BMP2, IGF1 und (Pro)Insulin wurden in den Seren dieser Frakturpatienten gemessen. In Frakturpatienten wurden in 5% der Seren aAB gegen den IGF1R und in 6% gegen den IR gefunden. Das Auftreten von IGF1R- und IR-aAB wurde nicht induziert und war nicht mit dem Heilungsergebnis assoziiert. BMP7-aAB wurden in 1-2,5% gesunder Probanden und Frakturpatienten, die nicht mit rhBMP7 behandelt wurden, detektiert. Patienten, die mit rhBMP7 behandelt wurden, zeigten ein höheres Auftreten der BMP7-aAB Positivität mit 6% zum Zeitpunkt der Operation und 18% vier Wochen nach der Operation. BMP2-aAB wurden in 2% der gesunden Kontrollen und 6% der mit rhBMP7-behandelten Frakturpatienten entdeckt. Bei der Charakterisierung des biologischen Effekts der BMP7-aAB durch einen zell-basierten Reporter-Assay, zeigte sich ein neutralisierender Effekt in Proben mit hohem BMP7-aAB Titer. Als das wichtigste Kriterium für klinische Relevanz wurde die Konsolidierung untersucht. Das Vorhandensein von BMP-aAB wurde nicht signifikant mit der Konsolidierung in Zusammenhang gebracht. Zusammenfassend wurden neue diagnostische Assays zur Detektion von aAB gegen Wachstumsfaktoren und deren Rezeptoren generiert und angewandt um aAB in Seren von Frakturpatienten zu messen. Keiner der identifizierten aAB war negativ mit dem Heilungsprozess assoziiert. Bedenken bezüglich der Sicherheit von rhBMP7 Behandlungen sind berechtigt, da die Anwendung aAB gegen BMP7 induziert, die den BMP7-Signalweg blockieren. / Regeneration of bone during fracture healing includes concerted actions of growth factors. Some fractures show delayed healing or non-union due to as yet unknown reasons. Neutralizing autoantibodies (aAB) against growth factors or their receptors might influence and potentially impair the bone healing capacity. In this study, a cohort of 265 fracture patients with different treatment regimen and healing outcomes were analysed. Autoantibodies against IGF1 receptor, insulin receptor, BMP7, BMP2, IGF1 and (pro)insulin were measured in sera of these fracture patients. The prevalence of aAB against IGF1R and IR was 5% and 6% in fracture patients, respectively. The appearance of IGF1R- and IR-aAB was not induced by the surgical intervention and was unrelated to the healing outcome. BMP7-aAB were found in 1-2.5% of healthy subjects and in fracture patients that were not treated with rhBMP7. Patients that had received rhBMP7 treatment showed a higher incidence of BMP7-aAB positivity of 6% at surgery and 18% four weeks post surgery. BMP2-aAB were found in 2% of healthy controls and 6% of the fracture patients that were treated with rhBMP7. Characterizing the biological effect of BMP7-aAB in a cell-based reporter assay, a neutralizing effect was observed for samples with high titres. As the most relevant clinical outcome, the criterion consolidation was analysed defining whether the fracture gap was closed after six months or not. The presence of BMP-aAB was not significantly associated with the healing outcome. In summary, novel diagnostic assays for the detection and quantification of growth factor and receptor aAB were generated and used to determine aAB in sera from fracture patients. None of the identified aAB were negatively associated with the regeneration process or healing outcome. Ongoing concerns regarding the safety of rhBMP7 treatment are justified as the biological treatment induces aAB against BMP7 that block the BMP signal transduction.

Die Behandlung entzündlicher, tumorbedingter, dysmorphischer oder posttraumatischer Defekte des menschlichen Skeletts hat besonders in den letzten drei Jahrzehnten neben dem Standard der Behandlung, der Übertragung von körpereigenen Hartgeweben und in konserviertem Zustand übertragenem Spendermaterial, auch Knochenersatzmittel in der Therapie etabliert und in Qualität und Quantität der Eingriffe an Bedeutung gewonnen. Die Diskussion über die Übertragbarkeit von Infektionskrankheiten durch Gewebe aus Knochenbanken hat den Einsatz von konserviertem Spenderknochen in den Hintergrund treten lassen. Aus diesem Grunde wird immer wieder nach geeigneten Knochenersatzmaterialien gesucht. Zahlreiche Implantate aus verschiedenen physikalisch und chemisch differenten Stoffgruppen wurden auf ihre Eignung zum Knochenersatz getestet. Ein ideales Material wurde bislang nicht gefunden. Im Tierversuchsmodell und in der klinischen Anwendung beim Menschen wurden verschiedene Knochenersatzmaterialien hinsichtlich der Dynamik der Knochenumbauprozesse mittels nuklearmedizinscher und röntgenologischer Verfahren evaluiert und im Ergebnis des knöchernen Substitues histologisch bezüglich ihrer Wertigkeit für den funktionellen Knochenersatz untersucht. Im Vergleich zum autogenen Knochentransplantat entstanden im Ergebnis der Implantation osteoinduktiver und osteokonduktiv wirkender Knochenersatzmaterialien Substitute, die ausnahmslos und vor allem bei den keramischen Implantaten als unvollständige Restitution zu werten waren. / Alongside the standard donor bone transfer, bone substitutes have established themselves, improved in quality and are being increasingly used in the surgical treatment of dysmorphic defects or defects following inflammation, tumor surgery or trauma, particularly in the last three decades. With the discussion about infectious disease transmission through tissue from bone banks, the use of donor bone has receded into the background. For this reason, suitable bone substitutes are being sought constantly. Implants of many different physical and chemical substance groups have been tested for their suitability as bone substitutes, but an ideal material has yet to be found. In animal experiment models and their clinical application in humans, various bone substitutes have been evaluated for the dynamic of the resulting bone formation using nuclear medical and radiological procedures and have been examined histologically for their value as functional bone substitutes. Compared to autogenous bone grafts, the bone substitutes which have emerged as the result of the implantation of osteoinductive and osteoconductive materials have, without exception and particularly in the case the ceramic implants, shown incomplete restitution.

Introdução: Baixas concentrações séricas de esclerostina foram descritas em pacientes com Espondilite Anquilosante (EA). No entanto, não existem dados sobre a importância deste inibidor da via de sinalização Wnt em pacientes com EA durante o tratamento com anti fator de necrose tumoral alfa (TNFa). Objetivos: Avaliar longitudinalmente os níveis séricos de esclerostina e sua associação com inflamação e densidade mineral óssea (DMO) em pacientes com EA em tratamento com anti-TNFa. Métodos: Trinta pacientes com EA em atividade foram avaliados no início, 6 e 12 meses, após terapia anti-TNFa em relação aos parâmetros clínicos (BASDAI, BASFI, BASMI e ASQoL), marcadores inflamatórios e dano radiológico basal (mSASSS). Trinta indivíduos saudáveis pareados por idade e sexo constituíram o grupo controle. As análises laboratoriais de esclerostina e da ligação de esclerostina ao receptor LRP6 e a DMO foram realizadas nos pacientes nos mesmos períodos de avaliação e comparadas aos controles. Resultados: Na avaliação inicial, pacientes com EA apresentavam menores concentrações séricas de esclerostina [60,5 (32,7) vs. 96,7 (52,9) pmol/l,P=0,002] e níveis similares de ligação de esclerostina ao receptor LRP6 (P=0,387) em relação aos controles. Foi observado melhora do BASDAI, BASFI, BASMI, ASQoL comparando tempo basal vs. 6 vs. 12 meses (P<0,01). Concomitantemente, observou-se um aumento gradual da DMO da coluna lombar (P<0,001) e no início do estudo os pacientes apresentavam uma correlação positiva entre avaliação radiológica basal (mSASSS) e a DMO da coluna lombar (r=0,468, P<0,01). Foi observada também uma redução dos marcadores inflamatórios comparando tempo basal vs. 6 vs. 12 meses (P<0,01). Os níveis de esclerostina aumentaram progressivamente após o tratamento com anti-TNFa [60,5 (32,7) vs. 67,1 (31,9) vs. 72,7 (32,3) pmol/l, P<0,001]. Entretanto, após 12 meses de terapia anti-TNFa as concentrações séricas de esclerostina permaneceram significativamente mais baixos em relação os controles [72,7 (32,3) vs. 96,7 (52,9) pmol/l, P=0,038]. Além disso, aos 12 meses, os níveis séricos de esclerostina ficaram mais baixos nos 10 pacientes que ainda apresentavam proteína C reativa elevada (PCR=5mg/l), comparados aos pacientes que apresentaram normalização dos níveis de PCR (P=0,004). Interessantemente, estes 10 pacientes com inflamação persistente já apresentavam concentrações séricas mais baixas de esclerostina quando comparados aos demais pacientes (P=0,023) antes do tratamento com anti- TNFa. A análise de regressão logística demonstrou que os pacientes com EA com níveis baixos de esclerostina apresentam um risco aumentado de apresentar PCR alta após 12 meses de tratamento (odds ratio = 7,43, 95% IC 1,23-45,01, P=0,020) quando comparados aos pacientes com níveis altos de esclerostina no tempo basal. Conclusão: Concentrações persistentemente baixas de esclerostina estão associados a inflamação contínua em pacientes com EA tratados com terapia anti-TNFa. / Introduction: Sclerostin levels have been reported to be low in ankylosing spondylitis (AS), but there is no data regarding the possible role of this Wnt inhibitor during anti tumor necrosis factor alpha (TNFa) therapy. Objectives: The present study longitudinally evaluated sclerostin levels, inflammatory markers and bone mineral density (BMD) in AS patients under anti-TNFa therapy. Methods: Thirty active AS patients were assessed at baseline, 6 and 12 months after anti-TNFa therapy regarding clinical parameters (BASDAI, BASFI, BASMI and ASQoL), inflammatory markers, BMD and baseline radiographic damage (mSASSS). Thirty age- and sex-matched healthy individuals comprised the control group. Patients\' sclerostin levels, sclerostin binding LRP6 and BMD were evaluated at the same time points and compared to controls. Results: At baseline, AS patients had lower sclerostin levels [60.5 (32.7) vs. 96.7 (52.9) pmol/l, P=0.002] and comparable sclerostin binding to LRP6 (P=0.387) than controls. Improvement of BASDAI, BASFI, BASMI, ASQoL was observed at baseline vs. 6 vs. 12 months (P<0.01). Concomitantly, a gradual increase in spine BMD (P<0.001) and a positive correlation between baseline mSASSS and spine BMD was found (r=0.468, P<0.01). Inflammatory parameters reduction was observed comparing baseline vs. 6 vs. 12 months (P<0.01). Sclerostin levels progressively increased [60.5 (32.7) vs. 67.1 (31.9) vs. 72.7 (32.3) pmol/l, P<0.001] after anti-TNFa treatment. At 12 months, the sclerostin levels remained significantly lower in patients compared to controls [72.7 (32.3) vs. 96.70 (52.85) pmol/l, P=0.038]. Moreover, sclerostin serum levels at 12 months were lower in the 10 patients with high CRP (=5mg/l) compared to the other 20 patients with normal CRP (P=0.004). Of note, these 10 patients with persistent inflammation also had lower sclerostin serum levels at baseline compared to the other patients (P=0.023). Univariate logistic regression analysis demonstrated that AS patients with lower sclerostin serum levels had an increased risk to have high CRP at 12 months (odds ratio=7.43, 95% CI 1.23-45.01, P=0.020) than those with higher sclerostin values. Conclusion: Persistent low sclerostin levels may underlie continuous inflammation in AS patients under anti-TNFa therapy.

Introdução: Baixas concentrações séricas de esclerostina foram descritas em pacientes com Espondilite Anquilosante (EA). No entanto, não existem dados sobre a importância deste inibidor da via de sinalização Wnt em pacientes com EA durante o tratamento com anti fator de necrose tumoral alfa (TNFa). Objetivos: Avaliar longitudinalmente os níveis séricos de esclerostina e sua associação com inflamação e densidade mineral óssea (DMO) em pacientes com EA em tratamento com anti-TNFa. Métodos: Trinta pacientes com EA em atividade foram avaliados no início, 6 e 12 meses, após terapia anti-TNFa em relação aos parâmetros clínicos (BASDAI, BASFI, BASMI e ASQoL), marcadores inflamatórios e dano radiológico basal (mSASSS). Trinta indivíduos saudáveis pareados por idade e sexo constituíram o grupo controle. As análises laboratoriais de esclerostina e da ligação de esclerostina ao receptor LRP6 e a DMO foram realizadas nos pacientes nos mesmos períodos de avaliação e comparadas aos controles. Resultados: Na avaliação inicial, pacientes com EA apresentavam menores concentrações séricas de esclerostina [60,5 (32,7) vs. 96,7 (52,9) pmol/l,P=0,002] e níveis similares de ligação de esclerostina ao receptor LRP6 (P=0,387) em relação aos controles. Foi observado melhora do BASDAI, BASFI, BASMI, ASQoL comparando tempo basal vs. 6 vs. 12 meses (P<0,01). Concomitantemente, observou-se um aumento gradual da DMO da coluna lombar (P<0,001) e no início do estudo os pacientes apresentavam uma correlação positiva entre avaliação radiológica basal (mSASSS) e a DMO da coluna lombar (r=0,468, P<0,01). Foi observada também uma redução dos marcadores inflamatórios comparando tempo basal vs. 6 vs. 12 meses (P<0,01). Os níveis de esclerostina aumentaram progressivamente após o tratamento com anti-TNFa [60,5 (32,7) vs. 67,1 (31,9) vs. 72,7 (32,3) pmol/l, P<0,001]. Entretanto, após 12 meses de terapia anti-TNFa as concentrações séricas de esclerostina permaneceram significativamente mais baixos em relação os controles [72,7 (32,3) vs. 96,7 (52,9) pmol/l, P=0,038]. Além disso, aos 12 meses, os níveis séricos de esclerostina ficaram mais baixos nos 10 pacientes que ainda apresentavam proteína C reativa elevada (PCR=5mg/l), comparados aos pacientes que apresentaram normalização dos níveis de PCR (P=0,004). Interessantemente, estes 10 pacientes com inflamação persistente já apresentavam concentrações séricas mais baixas de esclerostina quando comparados aos demais pacientes (P=0,023) antes do tratamento com anti- TNFa. A análise de regressão logística demonstrou que os pacientes com EA com níveis baixos de esclerostina apresentam um risco aumentado de apresentar PCR alta após 12 meses de tratamento (odds ratio = 7,43, 95% IC 1,23-45,01, P=0,020) quando comparados aos pacientes com níveis altos de esclerostina no tempo basal. Conclusão: Concentrações persistentemente baixas de esclerostina estão associados a inflamação contínua em pacientes com EA tratados com terapia anti-TNFa. / Introduction: Sclerostin levels have been reported to be low in ankylosing spondylitis (AS), but there is no data regarding the possible role of this Wnt inhibitor during anti tumor necrosis factor alpha (TNFa) therapy. Objectives: The present study longitudinally evaluated sclerostin levels, inflammatory markers and bone mineral density (BMD) in AS patients under anti-TNFa therapy. Methods: Thirty active AS patients were assessed at baseline, 6 and 12 months after anti-TNFa therapy regarding clinical parameters (BASDAI, BASFI, BASMI and ASQoL), inflammatory markers, BMD and baseline radiographic damage (mSASSS). Thirty age- and sex-matched healthy individuals comprised the control group. Patients\' sclerostin levels, sclerostin binding LRP6 and BMD were evaluated at the same time points and compared to controls. Results: At baseline, AS patients had lower sclerostin levels [60.5 (32.7) vs. 96.7 (52.9) pmol/l, P=0.002] and comparable sclerostin binding to LRP6 (P=0.387) than controls. Improvement of BASDAI, BASFI, BASMI, ASQoL was observed at baseline vs. 6 vs. 12 months (P<0.01). Concomitantly, a gradual increase in spine BMD (P<0.001) and a positive correlation between baseline mSASSS and spine BMD was found (r=0.468, P<0.01). Inflammatory parameters reduction was observed comparing baseline vs. 6 vs. 12 months (P<0.01). Sclerostin levels progressively increased [60.5 (32.7) vs. 67.1 (31.9) vs. 72.7 (32.3) pmol/l, P<0.001] after anti-TNFa treatment. At 12 months, the sclerostin levels remained significantly lower in patients compared to controls [72.7 (32.3) vs. 96.70 (52.85) pmol/l, P=0.038]. Moreover, sclerostin serum levels at 12 months were lower in the 10 patients with high CRP (=5mg/l) compared to the other 20 patients with normal CRP (P=0.004). Of note, these 10 patients with persistent inflammation also had lower sclerostin serum levels at baseline compared to the other patients (P=0.023). Univariate logistic regression analysis demonstrated that AS patients with lower sclerostin serum levels had an increased risk to have high CRP at 12 months (odds ratio=7.43, 95% CI 1.23-45.01, P=0.020) than those with higher sclerostin values. Conclusion: Persistent low sclerostin levels may underlie continuous inflammation in AS patients under anti-TNFa therapy.

<p>Bone formation and bone healing were studied in the mandible, tibia and skull bones in adult, healthy and estrogen deficient rabbits implanted with different bone substitutes. </p><p>In the first study an evaluation of the differences in bone regeneration in and around solid (Alveograf *) and porous hydroxyapatite (Interpore 200*) was undertaken. The implant material was placed into experimentally made bone defects and in half of the defects hydroxyapatite was mixed with a fibrin sealant (Tisseel *). The material alone or mixed with Tisseel was also placed subperiostally in the mandible. The observation time was six month. No difference in bone regeneration was found between solid or porous hydroxyapatite granulas and the addition of Tisseel* did not seem to disturb the bone healing process. The implant material placed subperiostally did not induce bone formation nor did it provoke any bone resorption. The addition of Tisseel made the implant material much easier to handle and retain in the tissue during surgery.</p><p>Bone healing around hydroxyapatite implants was also evaluated in the second study. Experimental cavities in the mandible and tibia were filled with hydroxyapatite in granules or blocks (Interpore 200*) but now with or without autolyzed, antigen-extracted, allogeneic bone (AAA). Also in this study Tisseel* was used to facilitate the handling of the material. All cavities implanted with AAA-bone, regardless of the combination with hydroxyapatite or Tisseel, demonstrated excessive bone formation resembling exostosis formation. Thus, hydroxyapatite, both as granules and blocks, can be successfully combined with AAA bone utilizing the bone inductive capacity of AAA bone.</p><p>The same model was used to study the healing in ovariectomized animals in the third study. Bone cavities were implanted with or without AAA bone and left to heal. The results indicate that the osteoinductive capacity of AAA bone is in operation also in animals deprived of a normal estrogen production.</p><p>The effect of using AAA bone prior to implant insertion was studied in paper four. The bone-implant contact was significant higher when AAA bone had been used. The implant stability did not seem to be affected.</p><p>In paper five defects were made in skull and tibial bone in estrogen deficient animals. The deficiency of estrogen was confirmed through blood analysis, the decrease in the weight of uterus and bone mineral density. The whole body scanning with DEXA showed that the ovariectomized animals developed osteopenia. Various degree of bone formation was seen in the defects due to the influence of the bone inductive substance AAA bone. </p><p>The studies indicate that a conductive material like hydroxyapatite in granules or blocks could be useful in oral reconstructive surgery. The combination with AAA bone enhanced the bone formation in calvarial and tibial bone in healthy and estrogen deficient animals. Tisseel* could be used to facilitate handling and retention of the material in the intended position during the healing process without negative effects. </p>

Postmenopausal osteoporosis is a disease characterized by bone loss and increased risk of fracture, and represents a significant burden on the Canadian health care system. Current treatments lack the ability to simultaneously address the therapeutic needs for promoting bone formation and inhibiting resorption. Our approach employs a novel conjugate drug in which an anabolic agent (EP4 receptor agonist) is reversibly joined with an anti-resorptive agent (alendronate) through a linker. This allows the bone-targeting ability of alendronate to deliver the EP4 agonist to bone sites, thereby mitigating the side effects associated with systemic administration of the EP4 agonist. This study investigated the in vivo efficacy of this drug in a curative experiment to treat postmenopausal osteoporosis using an ovariectomized rat model. Results showed that conjugate treatment dose-dependently stimulated bone formation and restored ovariectomy-induced bone loss, and conjugation between alendronate and the EP4 agonist was crucial to the drug’s anabolic effect.

Postmenopausal osteoporosis is a disease characterized by bone loss and increased risk of fracture, and represents a significant burden on the Canadian health care system. Current treatments lack the ability to simultaneously address the therapeutic needs for promoting bone formation and inhibiting resorption. Our approach employs a novel conjugate drug in which an anabolic agent (EP4 receptor agonist) is reversibly joined with an anti-resorptive agent (alendronate) through a linker. This allows the bone-targeting ability of alendronate to deliver the EP4 agonist to bone sites, thereby mitigating the side effects associated with systemic administration of the EP4 agonist. This study investigated the in vivo efficacy of this drug in a curative experiment to treat postmenopausal osteoporosis using an ovariectomized rat model. Results showed that conjugate treatment dose-dependently stimulated bone formation and restored ovariectomy-induced bone loss, and conjugation between alendronate and the EP4 agonist was crucial to the drug’s anabolic effect.

Aims: This study uses radiological and clinical evaluations of the healing of endosseous titanium implants presented with different surface characteristics in the clinical situation (paper I-III) and experimentally to describe the early bone healing in maxillary sinus membrane elevation with and without the use of grafting material (paper IV). Material and methods: In paper I, 136 patients were treated with 394 dental implants – 199 were oxidized titanium implants (Nobel Biocare TiUnite) and 195 were turned titanium surface implants (Nobel Biocare Mark III). Implant survival rates were retrospectively investigated after a minimum of five months after functional loading of the implants. At the five-year follow-up (paper II), eight patients were deceased and 128 were invited. Twenty-five patients refrained from participating in the study. The remaining 103 patients (287 implants – 133 with a turned surface and 154 with an oxidized surface) were examined after at least five years of functional loading. Clinical examinations of bleeding on probing (BoP) and pocket depth (PD) were performed. Intraoral radiographs were used to assess marginal bone levels (MBLs). In paper III, 28 patients were subjected to autologous bone graft and delayed implant placement, with a total of 92 dental implants. Thirteen patients received 47 implants with a turned surface and 15 patients received 45 implants with an oxidized surface. After a minimum of five years of functional loading, all patients were clinically examined regarding PD and BoP. The MBL was measured in intraoral radiographs. Cone beam computed tomography (CBCT) was used to evaluate the apical bone level (ABL) of the implants and intra-sinus conditions. The experimental study (paper IV) used nine adult male tufted capuchin primates (Cebus apella). Eight animals were subjected to bilateral maxillary sinus membrane elevation using a lateral replaceable bone window technique. One oxidized dental implant was placed in the residual bone of the sinus floor, protruding into the maxillary sinus cavity on both sides. In four animals, one sinus was left without any additional treatment, while the contralateral sinus was filled with autologous bone grafts from the tibia. In two animals, the implants were inserted under the elevated sinus membrane on both sides. In two animals, the sinus membrane was totally removed bilaterally before placement of implants. The animals were euthanized after 10 (n=4) or 45 (n=4) days. One non-operated animal representing pristine tissue conditions served as the control. The maxillary sinuses with implants were retrieved and further processed to prepare light microscopic ground sections or decalcified sections for immunohistochemical analyses. Results: In paper I seven implants were lost in five patients – six in the maxilla and one in the mandible. All failed implants were Mark III turned implants. The overall implant survival rate was 98.2% with a survival rate of 96.4% for implants with turned surface after a minimum of five months after functional loading. In paper II, one additional oxidized implant failed, giving an overall cumulative survival rate of 94.7 and 99.4%, respectively, after at least five years of functional loading. There was no difference for BoP, PD, or MBL between turned and oxidized implants. A total of two implants, three oxidized and one turned, showed a PD &gt; 3 mm, MBL &gt; 4 mm, and BoP. However, none of these were associated with suppurative infection on examination. In paper III no difference was found between the two implants surfaces used in terms of PD, BoP, MBL, or ABL. Pathological reactions to the sinus membrane were seen in four of the patients (14%). Radiographic signs of sinus pathology were not correlated to either survival rate of the implants or any of the investigated parameters. In the experimental paper IV, bone formation started from the bottom of the sinus floor, sprouting into the granulation tissue along the implant surface under the elevated membrane irrespective of time and surgical technique. Bone formation was not seen in direct conjunction with the sinus membrane. A distinct expression of osteopontin was observed in the serous glands of deeper portion of the lamina propria in direct connection with the elevated sinus membrane and close to the implant within all groups. Conclusion: After more than five years of function in non-grafted patients, oxidized implants had a survival rate higher than turned implants, although this was not statistically significant. No difference was found in MBL, PD, or BoP. Grafting of the maxillary sinus floor with intra- orally harvested bone and delayed placement of either turned or oxidized implants resulted in equally high long-term survival rates, MBL, ABL, and BoP. Pathological findings in the maxillary sinus cavity, in terms of sinus membrane health, are few and not correlated to any of the other investigated parameters. In the experimental study bone formation after sinus membrane elevation with or without additional bone grafts started at the sinus floor and sprouted into the elevated space along the implant surface. Removal of the membrane resulted in less bone formation. The sinus membrane did not seem to present osteoinductive potential in sinus membrane elevation procedures.

Made available in DSpace on 2016-12-08T16:24:17Z (GMT). No. of bitstreams: 1 PGCA14MA130.pdf: 1998964 bytes, checksum: 145e149b4c0a26553d621c120349c867 (MD5) Previous issue date: 2014-02-21 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / New techniques for bone replacement have continuously been searched, to find new alternatives for treatment of fractures, bone tumors or any orthopedic disease requiring transplants or bone grafts. With that proposal, we performed surgical procedures in both sheep s tibia to evaluate the osteoregenerative capacity of biomaterials of different compositions. Eight female, mongrel sheeps, 12 months old, weighting on average 30kg were obtained for the animal study. Three bone defects, in both tibias of each animal, a total of six bone defects each, were produced, being four of them treated with four different types of biomaterials and two with autogenous bone grafts, as a control group. The biomaterials implanted were: hydroxyapatite (HA), beta-tricalcium phosphate (TCP-&#946;), hydroxyapatite/beta-tricalcium phosphate 60:40 (HA/TCP-&#946; 60:40) and the nanocomposite hydroxyapatite and alumina (HA/Al2O3 5%). The animals were allocated in two groups: Group 60 (n=04), in which the animals were euthanized sixty days after the implantation of the biomaterials and Group 90 (n=04), in which the animals were euthanized ninety days after the procedure. Were performed radiograph images on the preoperative period, on the immediate postoperative and at 30, 60 and 90 days of postoperative period, to excluded any previously disease or postoperative complications that could compromise this research. After euthanasia, the tibias were collected for macro and microscopic evaluation, which was accessed by scanning electron microscopy (SEM) and optic microscopy. The results suggest that HA, TCP-&#946; and HA/TCP-&#946; present a great osteoregenerative capacity. The last one seems to be the best for a long-term outcome, due its best control in the solubilization and releasing of calcium and phosphates ions through the biological environment during the bone formation. The nanocomposite HA/Al2O3 5% didn t show a good response on this study, and we suggest new researchs to better evaluate the potential and applicability of this new biomaterial / Novas técnicas para substituição de tecido ósseo têm sido continuamente pesquisadas, buscando novas alternativas para o tratamento de fraturas, tumores ósseos ou qualquer enfermidade ortopédica que indique o uso de transplantes ou enxertos ósseos. Com este intuito, foram realizados experimentos cirúrgicos em tíbias de ovinos, objetivando avaliar a capacidade osteoregenerativa de biomateriais em diferentes composições. Foram utilizadas oito ovelhas mestiças texel, com 12 meses de idade e peso médio de 30 kg. Foram produzidos três defeitos ósseos em ambas as tíbias dos animais, totalizando seis defeitos, sendo que quatro foram preenchidos por biomateriais, e dois por fragmentos ósseos retirados do próprio animal, funcionando como controle. Os materiais implantados foram: hidroxiapatita (HA), tricálcio fosfato-&#946; (TCP-&#946;), hidroxiapatita/tricálcio fosfato-&#946; (HA/TCP-&#946; 60/40) e o nanocompósito hidroxiapatita/alumina a 5% (HA/Al2O3 a 5%). Os animais foram alocados em dois grupos: Grupo 60 (n=04), em que os animais foram eutanasiados após 60 dias da colocação dos implantes e Grupo 90 (n=04), em que a eutanásia ocorreu 90 dias após a colocação dos implantes. Foram realizadas radiografias nos períodos pré-operatório, imediatamente após o procedimento e aos 30, 60 e 90 dias de pós-operatório, a fim de excluir qualquer alteração prévia ou complicação pós-operatória, capaz de comprometer a pesquisa. Após a eutanásia, foram coletadas as tíbias para avaliação macro e microscópica, por meio de microscopia eletrônica de varredura (MEV) e microscopia óptica. Os resultados encontrados sugerem uma boa capacidade de neoformação óssea com a HA, o TCP-&#946; e o composto bifásico HA/TCP-&#946; 60/40. Este último apresenta o melhor resultado a longo prazo, devido ao melhor controle na solubilização e liberação dos íons cálcio e fosfatos para o meio biológico durante o processo de neoformação óssea. O biomaterial nanocompósito HA/Al2O3 a 5% não apresentou resultados promissores neste estudo, e sugerem-se novas pesquisas a fim de investigar melhor o potencial e aplicabilidade deste novo biomaterial